Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 Confidential 11,487 Confidential 152 Confidential 11,639 11,487 152 11,639
2001 Confidential

12,533

 Confidential 147 Confidential 12,680 12,533 147 12,680
2002 691 15,223 136 139 827 15,362 15,914 275 16189
                   
In October 2002, Pennsylvania implemented confidential name-based HIV infection reporting only in areas outside the city of Philadelphia.
 

 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 Confidential Confidential Confidential Confidential
2001 Confidential Confidential Confidential Confidential
2002 569 691 136 827
         

In October 2002, Pennsylvania implemented confidential name-based HIV infection reporting only in areas outside the city of Philadelphia.
 

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 Confidential 1,224 Confidential 453
2001 Confidential 1,328 Confidential 501
         

In October 2002, Pennsylvania implemented confidential name-based HIV infection reporting only in areas outside the city of Philadelphia.
 

 

New Pediatric AIDS cases reported

Year
2000 15
2001 11

 

 

AIDS cases and annual rates per 100,000 population by Metropolitan area reported through 2001

 

 1999

2000

2001

Cumulative Totals
City No No. No. Adults / Adolescents Children under 13 Years old Total
Allentown 79 49 85 910 11 921
Harrisburg 74 69 123 1,134 8 1,142
Philadelphia 1,685 1,357 1,355 20,091 278 20,369
Pittsburgh 91 106 146 2,496 18 2,514
Scranton 12 19 13 442 4 446

 

In October 2002, Pennsylvania implemented confidential name-based HIV infection reporting only in areas outside the city of Philadelphia.
 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 28,136
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 27,796
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 340

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002
  PA USA
Men 21,875 680,909
Women 5,138 146,298
Total 27,013 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 1,811
New Adult/Adolescent AIDS Cases, Reported in 2001 1,829
New AIDS Cases in Children <13, Reported through December 2001 11

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  PA USA
Men 1,328 31,901
Women 501 11,082
Total 1,829 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 15,362
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 15,223
Estimated Number of Children Living with AIDS at the End of 2002 139
HIV Infection Cases Reported in 2002 569

In October 2002, Pennsylvania implemented confidential name-based HIV infection reporting only in areas outside the city of Philadelphia.
 

Total Deaths Reported through 2000, due to AIDS = 14,024
HIV Reporting Requirements ?   Yes, Name  Based. Name-based reporting was implemented in areas outside Philadelphia in October 2002. Reporting policies were not yet implemented in Philadelphia as of December 2002.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  Voluntary HIV testing; no specific law. State follows CDC guidelines; No specific law or language on testing for mothers and newborns.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  Yes, Local governments have interpreted state law to allow operation of syringe exchange programs as a public health intervention.
Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  Yes, Must stress abstinence and cover contraception.
Minors' Right to Consent to HIV/STD Services?  Yes. State explicitly classifies HIV/AIDS as an STD or infectious disease, for which minors may consent to testing and treatment.
 
 
Total Ryan White Funding, FY2000   $55,802,443 FY2002  $72,371,827

 

CDC HIV Prevention Funding for States
 FY2001  $4,969,099

 FY2003   $5,027,413
 

 

Total Federal and State Funding for ADAP, FY2001  $34,005,856

Definitions: ADAPs: AIDS Drug Assistance Programs (ADAPs), authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV-related prescription drugs to underinsured and uninsured individuals living with HIV/AIDS. Each state or territory administers its own ADAP.

 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation

Total ADAP Clients Served, June 2002  
  PA
#		 US
#
   2,213 80,035

 
ADAP Clients Served by Sex, June 2002  
  PA
#		 PA
%		 US
#		 US
%
  Male 1,793 81 62,034 78
  Female 420 19 16,702 21
  Total 2,213 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  PA
#		 PA
%		 US
#		 US
%
  White 974 44 29,426 37
  Black 819 37 26,245 33
  Hispanic 221 10 19,883 25
  Asian/Pacific Islander 22 1 795 1
  American Indian/Alaskan Native 22 1 795 1
  Other 155 7 795 1
  Total 2,213 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  PA
#		 PA
%		 US
#		 US
%
  <13 years old 22 1 795 1
  13-19 years old 22 1 0 1 0 1
  20-44 years old 1,350 61 50,105 63
  >44 years old 819 37 27,836 35
  Total 2,213 100 79,531 100

 
ADAP Clients Served by Income, June 2002  
  PA
#		 PA
%		 US
#		 US
%
  <100% FPL 199 9 38,175 48
  101-200% FPL 598 27 26,245 33
  201-300% FPL 310 14 8,748 11
  301-400% FPL 66 3 3,181 4
  >400% FPL 22 1 1,591 2
  Total 2,213 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  PA
#		 PA
%		 US
#		 US
%
  Medicaid 0 0 0 10
  Medicare 266 12 0 6
  Private 907 41 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  PA
$		 US
$
   31,877,000 878,610,754

 
National ADAP Budget by Source, FY 2002  
  PA
$		 PA
%		 US
$		 US
%
  ADAP Earmark 21,610,076 68 619,830,000 71
  Title II Base 901,924 3 28,886,192 3
  State 9,365,000 29 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 0 0 19,170,000 2
  Total 31,877,000 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  PA
$		 US
$
   2,238,099 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  PA
$		 PA
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 1,091,301 49 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 365,593 16 7,940,575 12
  Protease Inhibitors 627,900 28 16,433,502 25
  Opportunistic Infections/Other 153,307 7 9,015,329 14
  Total 2,238,099 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  PA
#		 US
#
   6,825 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  PA
#		 PA
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 3,092 45 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 1,168 17 23,933 10
  Protease Inhibitors 1,403 21 33,813 15
  Opportunistic Infections/Other 1,162 17 87,746 38
  Total 6,825 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  PA
$		 US
$
   NA 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  PA
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 13 NA
  Other Medications Covered 38 NA
  Total 69 NA